Rhythm Biosciences Ltd has released a press release.
Rhythm Successfully Validates Two Adjunct Biomarkers
Filed with ASX ·
6ix hasn’t read this filing yet.
Rhythm Biosciences Limited on 6ix
Story so far
Earlier from Rhythm Biosciences
- Revised CEO Contract and LTIP for all employees - amended
- Revised CEO Contract and LTIP initiated for all employees
- Addtl Clinical Trial Site Signed - First Patient Recruited
- Non-renounceable rights issue Offer
- Placement & Rights Offer to raise approximately $6 million
Later from Rhythm Biosciences
- New Clinical Trial Site Contracted and Recruiting
- Final Two Adjunct Biomarkers Technically Validated
- Rhythm Receives $1.1m R&D Tax Incentive
- Ethics Approval Received, New Clinical Trial Site Added
- ColoSTAT Prototype Complete, Outperforms FIT
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences